Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hardwell you say all this, but then you’ve also openly admitted that you’re keen to buy back in here again? Make it make sense m8
That's an alarming anecdote but not all that surprising. Mad has the same tone in his social media stuff, lots of emojis, he seems to find it all a bit amusing too, there isn't the humility you'd expect from presiding over a company that's now made cumulative losses of £1bn+.
Cash flow wise last year's annual report does have a rare lucid moment stating: "free cash flow positive from 2024 onwards." Can't see it ending will if that's another goalpost that gets moved.
Why read into Kelso being silent other than MM now owns 8% ?? All the "theories" are just hot air
Nothing has changed at all PMH...don't give the slightest F about shareholders. CEO's got it all tied up like a federation football so they don't matter.
Interestingly I was talking to a senior bod from THG Saturday morning. They were actually laughing about the fact the company makes no money...
The problem with THG remains...eventually MM will run out of other people's money. My advice to all invested here is keep an eye on cash...in versus out. And I don't mean the " £600m available facilities" as that's just a credit card...
Not at all my friend not to worried either way only 2000 shares quite interesting but GLA which ever company or position you have ummm
Decent uptick in beauty..holding the prices on myprotein was a disaster.
I struggle to see what is changing here..
1) giving shareholders less then 24 hours notice about trading update and conference call - again
2) nothing about strategic update
3) where Is Lord Allen that is being paid £400k?
4) premium listing news?
Shambles really..seen it so many times before…small uptick today and it will drift back down to mid-high 50’s..
Its a sh@t show .all good in the hood .......just hold
Kelso have their own agenda here dafad and have their own update to publish before the end of the month and I'd expect them maybe to come over the next few days what with NCC slightly rebounding.
I also expect they will be more than a tad perturbed at MM's Linkedin comments of 95% of advice not being taken and pushed to the side.
In addition because the jewel in the crown at the time, THG Nutrition, now seems to be regresssing and substantially losing sales and revenue it is extremely doubtful now that with those declining numbers that it prove attractive to new investors in a seperate listing. I suspect that they will see any seperate listing of THG Nutrition as a missed opportunity.
A 170p Bid was turned down as substantially undervaluing THG. Apollo Bid also abruptly ended without any numbers posted as others do, and two bids for THG Nutrition also. Now noticeably a large decline in sales and here we are tonight at 65p.
I wouldn't parody them and always be wary of Active Investors who become the quiet ones.
Could Kelso be privy to future Thg plans and therfore unable tocomment or trade.Intetesting times!
These guys got a bit excited yesterday, upped their short by 0.1%
Don't disagree with you Fredster that a rate cut or 2 wouldn't do any harm to prospects
Not quite favourable macros yet I think we need to interest rates come down here and across the pond when there will be more appetite for this type of stock. That said I don’t think it’s too far away.
Maybe not before the AGM, but I'm with crafty. Rightly or wrongly, MM hates it on the LSE, and has been very vocal that he thinks it is the wrong place for THG. He has been biding his time to get some better numbers/forecasts out, get cashflow into a better position, and await more friendly macro/financing conditions. With those conditions now in place, he has to pull the trigger on something sooner rather than later to get to a more favourable valuation for shareholders and retain support, and give him a platform to accelerate growth again. JMO
Fair price is 175. Because share quantity increase over 35%. 1.3b shares. I can not image over 200
Fair enough. I'm not convinced that anything will happen in the near term, but let's see.
Great Crafty, keep up the good work.
Yep IMHO it has to happen before AGM or at least update on a review to list on a different exchange and if there is percentage equity interest in one or more of the divisions he will let the market know.
Why spend 15M separating the 3 divs and then do SFA.
Interesting to see who the new ingeniuty appointment will be on the 1st June. MM seemed very excited about that :)
No comment from them thus far after todays rns
Hmm thats true isn't it? @Crafty - are you still expecting a "major event" from now until the AGM in order for MM and BOD to remain in their positions? I recall you repeatedly saying that something has to happen otherwise they will lose support.
Nothing "major" has happened yet and they all seem to be sitting reasonably pretty.
You said you wouldn't be back till the AGM rampy. What happened?
Thank you crafty 👍
As for the green box remark, be my guest, I have no time for people who reside in echo chambers
"unless you are prepared to wait 5 - 10 years"
Can't speak for the horizon of others but an 8-10 bagger over 5-10 years certainly beats inflation 🤔 I'd be reasonably content with that outcome.
Yespsb you promised 'out' as soon as SP hits 70s, twice since it has hit 70p.
Did you forget to set your sell order?
Next time we hit 70p I will remind you :)
Well done!!!.. yspb you have been awarded a Green box for a great post
Beauty markets are buoyant and thriving away from LSE
https://beautymatter.com/articles/galderma-stock-surges-in-debut
EQT AB–backed Swiss skincare company Galderma surged on its first day of trading, trading as high as 18% to 62.68 francs. It was the largest IPO placement volume in Switzerland since 2017 and could be one of the biggest flotations in Europe this year.
WHO: Galderma is the world's largest independent dermatology company, spun out of Nestlé in 2019 when a consortium led by private equity house EQT and including Singapore's GIC and the Abu Dhabi Investment Authority acquired the Nestlé Skin Health unit for $10 billion and rebranded it as Galderma. Since its inception in 1981, the business has been driven by a dedication to dermatology, delivering an innovative, science-based portfolio of sophisticated brands and services across aesthetics, consumer care, and prescription medicine. Galderma’s portfolio of flagship brands includes Restylane, Dysport, Azzalure, Alluzience, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac and Loceryl in therapeutic dermatology.
WHY: Sale is success for EQT, which had eyed an IPO since 2021; Galderma plans to repay debt with the offering proceeds.
IN THEIR OWN WORDS: Flemming Ørnskov, MD, MPH, Chief Executive Officer of Galderma, said, “As the newest member of SIX Swiss Exchange, I am proud that Galderma’s IPO has been such a success. Galderma has continually developed its market leading position by advancing dermatology for every skin story. As we begin trading today, I want to thank every single person in our business for their unwavering commitment over the years—without it, Galderma wouldn’t have achieved the success we have to date. We have a great future ahead of us as a listed company delivering cutting-edge, premium products to our customers across the full spectrum of dermatology through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.”
Jos Dijsselhof, CEO SIX, emphasized, “We are delighted to welcome Galderma to the SIX family. With this new addition, we are further strengthening our position as the leading go-to exchange in Europe for companies at the intersection of consumer and healthcare. I wish Galderma every success as a public company and look forward to partnering with Galderma on their future capital market endevours